skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease

Review

(2511) Views  (819) Full article downloads

Authors: Amir Hayat, Dhiren Haria, Moro O Salifu

Published Date August 2008 Volume 2008:2 Pages 195 - 200
DOI: http://dx.doi.org/10.2147/PPA.S2356

Amir Hayat, Dhiren Haria, Moro O Salifu

Division of Nephrology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA

Abstract: Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is deficient in the majority of patients with advanced kidney disease thereby predisposing to anemia. Since the approval of recombinant human erythropoietin (epoetin alfa) by the US FDA in 1989, epoetin alfa and similar agents now collectively known as erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of the erythropoietin-deficient anemia that occurs in most patients with CKD. In this review, we have outlined the considerations that need to be taken into account when prescribing ESA for the treatment of anemia in CKD.

Keywords: erythropoietin stimulating agents, chronic kidney disease, anemia








Readers of this article also read:

Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)
Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis
Are symbols useful and culturally acceptable in health-state valuation studies? An exploratory study in a multi-ethnic Asian population
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Managing anemia in patients with chronic heart failure: what do we know?
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Treatment of anemia in chronic kidney disease: known, unknown, and both
Mild and moderate pre-dialysis chronic kidney disease is associated with increased coronary artery calcium
Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease